List of Tables
    Table 1. Pulmonary Drugs CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Pulmonary Drugs Market Trends
    Table 3. Pulmonary Drugs Market Drivers
    Table 4. Pulmonary Drugs Market Challenges
    Table 5. Pulmonary Drugs Market Restraints
    Table 6. Global Pulmonary Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Pulmonary Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Pulmonary Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Pulmonary Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Pulmonary Drugs Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Pulmonary Drugs Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Pulmonary Drugs Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Pulmonary Drugs Sales by Manufacturer, (K Units), 2017-2022
    Table 14. Global Pulmonary Drugs Sales Share by Manufacturer, 2017-2022
    Table 15. Global Pulmonary Drugs Price by Manufacturer (2017-2022) & (USD/Unit)
    Table 16. Global Pulmonary Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Pulmonary Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Drugs as of 2021)
    Table 18. Top Players of Pulmonary Drugs in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Pulmonary Drugs Product Type
    Table 20. Date of International Manufacturers Enter into Pulmonary Drugs Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Pulmonary Drugs Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Pulmonary Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Pulmonary Drugs Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Pulmonary Drugs Sales by Players, (K Units), 2020, 2021 & 2022
    Table 26. United States Pulmonary Drugs Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Pulmonary Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Pulmonary Drugs Sales in Volume by Region (2017-2022) & (K Units)
    Table 29. Global Pulmonary Drugs Sales in Volume Forecast by Region (2023-2028) & (K Units)
    Table 30. Global Pulmonary Drugs Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Pulmonary Drugs Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Pulmonary Drugs Sales in Volume by Country (2017-2028) & (K Units)
    Table 33. North America Pulmonary Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Pulmonary Drugs Sales in Volume by Region (2017-2028) & (K Units)
    Table 35. Asia Pacific Pulmonary Drugs Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Pulmonary Drugs Sales in Volume by Country (2017-2028) & (K Units)
    Table 37. Europe Pulmonary Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Pulmonary Drugs Sales in Volume by Country (2017-2028) & (K Units)
    Table 39. Latin Americaa Pulmonary Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Pulmonary Drugs Sales in Volume by Country (2017-2028) & (K Units)
    Table 41. Middle East and Africa Pulmonary Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Sanofi SA Corporation Information
    Table 43. Sanofi SA Description and Business Overview
    Table 44. Sanofi SA Pulmonary Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 45. Sanofi SA Pulmonary Drugs Product
    Table 46. Sanofi SA Recent Development
    Table 47. Meda Pharmaceuticals Corporation Information
    Table 48. Meda Pharmaceuticals Description and Business Overview
    Table 49. Meda Pharmaceuticals Pulmonary Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 50. Meda Pharmaceuticals Product
    Table 51. Meda Pharmaceuticals Recent Development
    Table 52. Circassia Pharmaceuticals Plc. Corporation Information
    Table 53. Circassia Pharmaceuticals Plc. Description and Business Overview
    Table 54. Circassia Pharmaceuticals Plc. Pulmonary Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 55. Circassia Pharmaceuticals Plc. Product
    Table 56. Circassia Pharmaceuticals Plc. Recent Development
    Table 57. AstraZeneca Plc. Corporation Information
    Table 58. AstraZeneca Plc. Description and Business Overview
    Table 59. AstraZeneca Plc. Pulmonary Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 60. AstraZeneca Plc. Product
    Table 61. AstraZeneca Plc. Recent Development
    Table 62. GlaxoSmithKline Plc. Corporation Information
    Table 63. GlaxoSmithKline Plc. Description and Business Overview
    Table 64. GlaxoSmithKline Plc. Pulmonary Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 65. GlaxoSmithKline Plc. Product
    Table 66. GlaxoSmithKline Plc. Recent Development
    Table 67. Mallinckrodt Pharmaceuticals Plc. Corporation Information
    Table 68. Mallinckrodt Pharmaceuticals Plc. Description and Business Overview
    Table 69. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 70. Mallinckrodt Pharmaceuticals Plc. Product
    Table 71. Mallinckrodt Pharmaceuticals Plc. Recent Development
    Table 72. Cheisi Farmaceutici S.p.A Corporation Information
    Table 73. Cheisi Farmaceutici S.p.A Description and Business Overview
    Table 74. Cheisi Farmaceutici S.p.A Pulmonary Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 75. Cheisi Farmaceutici S.p.A Product
    Table 76. Cheisi Farmaceutici S.p.A Recent Development
    Table 77. Zambon Company S.p.A Corporation Information
    Table 78. Zambon Company S.p.A Description and Business Overview
    Table 79. Zambon Company S.p.A Pulmonary Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 80. Zambon Company S.p.A Product
    Table 81. Zambon Company S.p.A Recent Development
    Table 82. Alaxia SAS Corporation Information
    Table 83. Alaxia SAS Description and Business Overview
    Table 84. Alaxia SAS Pulmonary Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 85. Alaxia SAS Product
    Table 86. Alaxia SAS Recent Development
    Table 87. Merck Sharp & Dohme Limited Corporation Information
    Table 88. Merck Sharp & Dohme Limited Description and Business Overview
    Table 89. Merck Sharp & Dohme Limited Pulmonary Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 90. Merck Sharp & Dohme Limited Product
    Table 91. Merck Sharp & Dohme Limited Recent Development
    Table 92. Key Raw Materials Lists
    Table 93. Raw Materials Key Suppliers Lists
    Table 94. Pulmonary Drugs Customers List
    Table 95. Pulmonary Drugs Distributors List
    Table 96. Research Programs/Design for This Report
    Table 97. Key Data Information from Secondary Sources
    Table 98. Key Data Information from Primary Sources
List of Figures
    Figure 1. Pulmonary Drugs Product Picture
    Figure 2. Global Pulmonary Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Pulmonary Drugs Market Size 2017-2028 (US$ Million)
    Figure 4. Global Pulmonary Drugs Sales 2017-2028 (K Units)
    Figure 5. United States Pulmonary Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Pulmonary Drugs Market Size 2017-2028 (US$ Million)
    Figure 7. United States Pulmonary Drugs Sales 2017-2028 (K Units)
    Figure 8. United States Pulmonary Drugs Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Pulmonary Drugs Market Share in Global, in Volume (K Units) 2017-2028
    Figure 10. Pulmonary Drugs Report Years Considered
    Figure 11. Product Picture of Inhaled Corticosteroids
    Figure 12. Product Picture of Long Acting Beta-2 Agonists
    Figure 13. Product Picture of Antihistamines
    Figure 14. Product Picture of Vasodilators
    Figure 15. Product Picture of Others
    Figure 16. Global Pulmonary Drugs Market Share by Type in 2022 & 2028
    Figure 17. Global Pulmonary Drugs Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 18. Global Pulmonary Drugs Sales Market Share in Value by Type (2017-2028)
    Figure 19. Global Pulmonary Drugs Sales by Type (2017-2028) & (K Units)
    Figure 20. Global Pulmonary Drugs Sales Market Share in Volume by Type (2017-2028)
    Figure 21. Global Pulmonary Drugs Price by Type (2017-2028) & (USD/Unit)
    Figure 22. United States Pulmonary Drugs Market Share by Type in 2022 & 2028
    Figure 23. United States Pulmonary Drugs Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 24. United States Pulmonary Drugs Sales Market Share in Value by Type (2017-2028)
    Figure 25. United States Pulmonary Drugs Sales by Type (2017-2028) & (K Units)
    Figure 26. United States Pulmonary Drugs Sales Market Share in Volume by Type (2017-2028)
    Figure 27. United States Pulmonary Drugs Price by Type (2017-2028) & (USD/Unit)
    Figure 28. Product Picture of Asthma & COPD
    Figure 29. Product Picture of Allergic Rhinitis
    Figure 30. Product Picture of Pulmonary Arterial Hypertension
    Figure 31. Product Picture of Cystic Fibrosis
    Figure 32. Product Picture of Others
    Figure 33. Global Pulmonary Drugs Market Share by Application in 2022 & 2028
    Figure 34. Global Pulmonary Drugs Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 35. Global Pulmonary Drugs Sales Market Share in Value by Application (2017-2028)
    Figure 36. Global Pulmonary Drugs Sales by Application (2017-2028) & (K Units)
    Figure 37. Global Pulmonary Drugs Sales Market Share in Volume by Application (2017-2028)
    Figure 38. Global Pulmonary Drugs Price by Application (2017-2028) & (USD/Unit)
    Figure 39. United States Pulmonary Drugs Market Share by Application in 2022 & 2028
    Figure 40. United States Pulmonary Drugs Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 41. United States Pulmonary Drugs Sales Market Share in Value by Application (2017-2028)
    Figure 42. United States Pulmonary Drugs Sales by Application (2017-2028) & (K Units)
    Figure 43. United States Pulmonary Drugs Sales Market Share in Volume by Application (2017-2028)
    Figure 44. United States Pulmonary Drugs Price by Application (2017-2028) & (USD/Unit)
    Figure 45. North America Pulmonary Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 46. North America Pulmonary Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 47. U.S. Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Canada Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Europe Pulmonary Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 50. Europe Pulmonary Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 51. Germany Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 52. France Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 53. U.K. Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Italy Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 55. Russia Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Asia-Pacific Pulmonary Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 57. Asia-Pacific Pulmonary Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 58. China Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 59. Japan Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. South Korea Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. India Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. Australia Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Taiwan Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 64. Indonesia Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 65. Thailand Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 66. Malaysia Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 67. Philippines Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 68. Latin America Pulmonary Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 69. Latin America Pulmonary Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 70. Mexico Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 71. Brazil Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 72. Argentina Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 73. Middle East & Africa Pulmonary Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 74. Middle East & Africa Pulmonary Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 75. Turkey Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 76. Saudi Arabia Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 77. U.A.E Pulmonary Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 78. Pulmonary Drugs Value Chain
    Figure 79. Pulmonary Drugs Production Process
    Figure 80. Channels of Distribution
    Figure 81. Distributors Profiles
    Figure 82. Bottom-up and Top-down Approaches for This Report
    Figure 83. Data Triangulation
    Figure 84. Key Executives Interviewed